Last reviewed · How we verify
Ppsv23 (ppsv23)
Pneumovax 23 is a pneumococcal vaccine used to prevent pneumococcal disease in adults. It is marketed by Pfizer Inc. The vaccine works by introducing capsular polysaccharides of 23 Streptococcus pneumoniae serotypes to the body. This stimulates the immune system to produce antibodies that fight the bacteria. Pneumovax 23 is indicated for adults 50 years and older, as well as those with functional or anatomic asplenia, HIV infection, chronic heart disease, or chronic lung disease. It is administered via intramuscular or subcutaneous injection. The vaccine has been widely used and has a significant commercial presence.
At a glance
| Generic name | ppsv23 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Vaccine |
| Target | Streptococcus pneumoniae |
| Modality | Vaccine |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Prevention of invasive disease caused by Streptococcus pneumoniae in adults 50 years of age or older
- Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with functional or anatomic asplenia
- Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with HIV infection
- Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with chronic heart disease, including congestive heart failure, coronary artery disease, or cardiac transplantation
- Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with chronic lung disease, including chronic obstructive pulmonary disease (COPD) and asthma
- Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with cerebrospinal fluid leak
- Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with sickle cell disease
- Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with alcohol use disorder
- Prevention of pneumococcal meningitis in children 2 years of age or older with functional or anatomic asplenia
- Prevention of pneumococcal meningitis in children 2 years of age or older with HIV infection
Common side effects
Drug interactions
- Live, attenuated vaccines
- Aluminum-containing vaccines
- Interferon-gamma
- Immunosuppressants
- Corticosteroids
Key clinical trials
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
- A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002) (PHASE1)
- Nasopharyngeal Carriage of S. Pneumoniae (NA)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination (PHASE3)
- Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (PHASE2)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 (PHASE3)
- Safety and Efficacy of wSp Vaccine in Young Children (PHASE2)
- Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ppsv23 CI brief — competitive landscape report
- Ppsv23 updates RSS · CI watch RSS
- Pfizer portfolio CI